Literature DB >> 25915731

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Rafael Carretero1, Ibrahim M Sektioglu1, Natalio Garbi1, Oscar C Salgado1, Philipp Beckhove2, Günter J Hämmerling1.   

Abstract

Tumor-associated eosinophilia is frequently observed in cancer. However, despite numerous studies of patients with cancer and mouse models of cancer, it has remained uncertain if eosinophils contribute to tumor immunity or are mere bystander cells. Here we report that activated eosinophils were essential for tumor rejection in the presence of tumor-specific CD8(+) T cells. Tumor-homing eosinophils secreted chemoattractants that guided T cells into the tumor, which resulted in tumor eradication and survival. Activated eosinophils initiated substantial changes in the tumor microenvironment, including macrophage polarization and normalization of the tumor vasculature, which are known to promote tumor rejection. Thus, our study presents a new concept for eosinophils in cancer that may lead to novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25915731     DOI: 10.1038/ni.3159

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  47 in total

Review 1.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 2.  Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors.

Authors:  Ramin Lotfi; James J Lee; Michael T Lotze
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

3.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

Authors:  R I Tepper; R L Coffman; P Leder
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

Review 4.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

5.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

6.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962

7.  CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.

Authors:  Natalio Garbi; Bernd Arnold; Siamon Gordon; Günter J Hämmerling; Ruth Ganss
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

8.  Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells.

Authors:  Ramin Lotfi; Gloria Isabelle Herzog; Richard Anthony DeMarco; Donna Beer-Stolz; James Joseph Lee; Anna Rubartelli; Hubert Schrezenmeier; Michael Thomas Lotze
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

9.  PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.

Authors:  David K Finlay; Ella Rosenzweig; Linda V Sinclair; Carmen Feijoo-Carnero; Jens L Hukelmann; Julia Rolf; Andrey A Panteleyev; Klaus Okkenhaug; Doreen A Cantrell
Journal:  J Exp Med       Date:  2012-11-26       Impact factor: 14.307

10.  Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process.

Authors:  Joerg Mattes; Mark Hulett; Wei Xie; Simon Hogan; Marc E Rothenberg; Paul Foster; Christopher Parish
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

View more
  156 in total

Review 1.  Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease.

Authors:  Hiam Abdala-Valencia; Mackenzie E Coden; Sergio E Chiarella; Elizabeth A Jacobsen; Bruce S Bochner; James J Lee; Sergejs Berdnikovs
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

2.  Granulocytes: Eosinophils enable the antitumour T cell response.

Authors:  Kirsty Minton
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

3.  Tumour vessel normalization and immune checkpoint blockade: a new synergism.

Authors:  Ruth Ganss
Journal:  Immunol Cell Biol       Date:  2017-05-23       Impact factor: 5.126

4.  Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Authors:  Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner
Journal:  JCI Insight       Date:  2017-04-20

5.  Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Authors:  Eva Knuplez; Rebecca Krier-Burris; Yun Cao; Gunther Marsche; Jeremy O'Sullivan; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-03-05       Impact factor: 4.962

6.  Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages.

Authors:  Hisashi Kanemaru; Fumihiro Yamane; Kiyoharu Fukushima; Takanori Matsuki; Takahiro Kawasaki; Isao Ebina; Kanako Kuniyoshi; Hiroki Tanaka; Kenta Maruyama; Kazuhiko Maeda; Takashi Satoh; Shizuo Akira
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

Review 7.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review.

Authors:  Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas
Journal:  Toxicol Res (Camb)       Date:  2015-08-11       Impact factor: 3.524

8.  Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.

Authors:  Shipra Gandhi; Manu Pandey; Nischala Ammannagari; Chong Wang; Mark J Bucsek; Lamya Hamad; Elizabeth Repasky; Marc S Ernstoff
Journal:  Immunotherapy       Date:  2020-02-17       Impact factor: 4.196

9.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

Authors:  Grit S Herter-Sprie; Shohei Koyama; Houari Korideck; Josephine Hai; Jiehui Deng; Yvonne Y Li; Kevin A Buczkowski; Aaron K Grant; Soumya Ullas; Kevin Rhee; Jillian D Cavanaugh; Neermala Poudel Neupane; Camilla L Christensen; Jan M Herter; G Mike Makrigiorgos; F Stephen Hodi; Gordon J Freeman; Glenn Dranoff; Peter S Hammerman; Alec C Kimmelman; Kwok-Kin Wong
Journal:  JCI Insight       Date:  2016-06-16

10.  Germline mutations and blood malignancy (Review).

Authors:  Yuping Gong; Jili Deng; Xia Wu
Journal:  Oncol Rep       Date:  2020-11-11       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.